Table 5 Correlations between USP22, SIRT1 and E-cadherin expression and PTC patients’ survival analysis
| Â | Survival Time (Months) | Survival rate (%) | P | ||||
|---|---|---|---|---|---|---|---|
(95% CI) | Means ±SE | Median ± SE (95% CI) | |||||
5-year Overall Survival | |||||||
 USP 22 | Low | 56.9 ± 2.4 | (52.3–61.56) | NR | 86.7 | 0.571 | |
High | 56.1 ± 1.7 | (52.68–59.49) | NR | 79.2 | |||
 SIRT1 | Low | 57.8 ± 1.7 | (54.45–61.17) | NR | 90.5 | 0.149 | |
High | 54.8 ± 2.2 | (50.4–59.16) | NR | 72.2 | |||
 E-cadherin | Low | 54.6 ± 2.2 | (50.34–58.83) | NR | 75 | 0.142 | |
High | 59.3 ± 0.6 | (58.07–60.6) | NR | 93.3 | |||
Overall | 56.4 ± 1.4 | (53.66–59.16) | NR | 82.1 |  | ||
5-year Disease-Free Survival | |||||||
 USP 22 | Low | 55.9 ± 2.9 | (50.16–61.57) | NR | 86.7 | 0.003 | |
High | 51 ± 1.8 | (47.4–54.51) | 50 ± 1.7 | (46.72–53.28) | 31.8 | ||
 SIRT 1 | Low | 55.3 ± 2.3 | (50.85–59.75) | NR | 75 | 0.01 | |
High | 50.2 ± 2.2 | (45.85–54.5) | 52 ± 5.4 | (41.51–62.49) | 29.4 | ||
 E-cadherin | Low | 50.5 ± 2.3 | (45.95–55.01) | 53 ± 3 | (47.13–58.87) | 39.1 | 0.03 |
High | 57 ± 1.6 | (53.81–60.19) | NR | 78.6 | |||
Overall | 52.9 ± 1.6 | (49.72–56.17) | NR | 54.1 |  | ||